Patents by Inventor Kirk W. Johnson

Kirk W. Johnson has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20180094053
    Abstract: The present disclosure relates, in general, to human antibodies against human interleukin 2 (IL-2) and methods of use of such antibodies for modulating IL-2 activity and use in the treatment of conditions such as cancer, autoimmune disease, or infection.
    Type: Application
    Filed: September 28, 2017
    Publication date: April 5, 2018
    Inventors: Marina Roell, Mark Rubinstein, Hassan Issafras, Llewelyn Lao, Ou Li, Daniel H. Bedinger, Kristin Camfield Lind, Agnes Choppin Holmes, Toshihiko Takeuchi, Lauren Schwimmer, Hoa Giang, Amer M. Mirza, Kirk W. Johnson
  • Publication number: 20180037658
    Abstract: The present disclosure relates, in general, to methods of treating or preventing post-prandial hypoglycemia after gastric bypass surgery using a negative modulator antibody that binds to the insulin receptor and modulates the action of insulin at the insulin receptor.
    Type: Application
    Filed: March 3, 2016
    Publication date: February 8, 2018
    Inventors: Kirk W. Johnson, Rajneesh Nath, Paul Rubin
  • Publication number: 20180030154
    Abstract: The present disclosure relates, in general, human antibodies against human parathyroid hormone receptor 1 (PTH1R) and methods of use of such antibodies in the treatment of cancer, Humoral Hypercalcemia of Malignancy (HHM), or Primary Hyperparathyroidism (PHPT) and Secondary Hyperparathyroidism (SHPT) and cachexia.
    Type: Application
    Filed: August 1, 2017
    Publication date: February 1, 2018
    Inventors: Raphael D. Levy, Hassan Issafras, Agnes Choppin Holmes, Kirk W. Johnson, Amer M. Mirza, Daniel H. Bedinger, Rachel A. Hunt, Toshihiko Takeuchi, Kiranjit Kaur Ahluwalia, Robyn Cotter
  • Patent number: 9234051
    Abstract: Methods for purifying fucoidan in extracts from brown seaweed are disclosed. In particular, methods of purifying fucoidan in the extract to remove heavy metal ions, bacterial and endotoxin contaminants, and other impurities are disclosed. The methods include the use of a chelating agent, selective precipitation, and filtration.
    Type: Grant
    Filed: May 1, 2014
    Date of Patent: January 12, 2016
    Assignees: BAXALTA INCORPORATED, BAXALTA GMBH
    Inventors: Patrick N. Shaklee, Jennifer Bahr-Davidson, Srinivasa Prasad, Kirk W. Johnson
  • Publication number: 20140328827
    Abstract: Methods for purifying fucoidan in extracts from brown seaweed are disclosed. In particular, methods of purifying fucoidan in the extract to remove heavy metal ions, bacterial and endotoxin contaminants, and other impurities are disclosed. The methods include the use of a chelating agent, selective precipitation, and filtration.
    Type: Application
    Filed: May 1, 2014
    Publication date: November 6, 2014
    Applicants: BAXTER INTERNATIONAL INC., BAXTER HEALTHCARE S.A.
    Inventors: Patrick N. Shaklee, Jennifer Bahr-Davidson, Srinivasa Prasad, Kirk W. Johnson
  • Patent number: 8859526
    Abstract: Methods for treating bleeding disorders using non-anticoagulant sulfated polysaccharides (NASPs) as procoagulants are disclosed. NASPs can be administered as single agents, or in combination with one another, or with other medications (such as factors VII, VIII and IX) to promote hemostasis. In particular, the use of NASPs in treatment of bleeding disorders, including congenital coagulation disorders, acquired coagulation disorders, and trauma induced hemorrhagic conditions is described.
    Type: Grant
    Filed: September 29, 2010
    Date of Patent: October 14, 2014
    Assignees: Baxter Healthcare S.A., Baxter International Inc.
    Inventor: Kirk W. Johnson
  • Patent number: 8771973
    Abstract: Methods for treating bleeding disorders using non-anticoagulant sulfated polysaccharides (NASPs) as procoagulants are disclosed. NASPs can be administered as single agents, or in combination with one another, or, with other medications (such as factors VII, VIII and IX) to promote hemostasis. In particular, the use of NASPs in treatment of bleeding disorders, including congenital coagulation disorders, acquired coagulation disorders, and trauma induced hemorrhagic conditions is described.
    Type: Grant
    Filed: May 19, 2011
    Date of Patent: July 8, 2014
    Assignees: Baxter Healthcare S.A., Baxter International Inc.
    Inventor: Kirk W. Johnson
  • Patent number: 8420697
    Abstract: The invention provides a method of improving one or more clinical outcomes of an individual experiencing an acute respiratory attack. The acute respiratory attack may include acute reversible bronchospasm, severe acute bronchospasm, or acute exacerbation of asthma. The method includes administering to an individual suffering from an acute respiratory attack an effective amount of bedoradrine or a pharmaceutically acceptable salt thereof in combination with a standard of care (SOC) treatment regimen.
    Type: Grant
    Filed: June 15, 2012
    Date of Patent: April 16, 2013
    Assignee: MediciNova, Inc.
    Inventors: Kazuko Matsuda, Yuichi Iwaki, Kirk W. Johnson
  • Publication number: 20120295982
    Abstract: A method of treating a human male patient is disclosed. Enterally administering bedoradrine or a pharmaceutically acceptable salt thereof to a human male patient who is suffering from a medical condition that is responsive to bedoradrine or a pharmaceutically acceptable salt thereof, is useful and benefits human males versus human females. A preferred mode of administration is oral administration.
    Type: Application
    Filed: February 21, 2012
    Publication date: November 22, 2012
    Inventor: Kirk W. Johnson
  • Publication number: 20120251632
    Abstract: The invention provides a method of improving one or more clinical outcomes of an individual experiencing an acute respiratory attack. The acute respiratory attack may include acute reversible bronchospasm, severe acute bronchospasm, or acute exacerbation of asthma. The method includes administering to an individual suffering from an acute respiratory attack an effective amount of bedoradrine or a pharmaceutically acceptable salt thereof in combination with a standard of care (SOC) treatment regimen.
    Type: Application
    Filed: June 15, 2012
    Publication date: October 4, 2012
    Inventors: Kazuko MATSUDA, Yuichi Iwaki, Kirk W. Johnson
  • Publication number: 20120129777
    Abstract: Methods for treating bleeding disorders using non-anticoagulant sulfated polysaccharides (NASPs) as procoagulants are disclosed. NASPs can be administered as single agents, or in combination with one another, or, with other medications (such as factors VII, VIII and IX) to promote hemostasis. In particular, the use of NASPs in treatment of bleeding disorders, including congenital coagulation disorders, acquired coagulation disorders, and trauma induced hemorrhagic conditions is described.
    Type: Application
    Filed: May 19, 2011
    Publication date: May 24, 2012
    Inventor: Kirk W. Johnson
  • Patent number: 8119657
    Abstract: Enantiomerically pure (S)-2-amino-1-(2-isopropylpyrazolo[1,5-a]pyridin-3-yl)propan-1-one, (S)-AV1013, is a candidate therapeutic for treating neuropathic pain, addiction behavior and drug withdrawal symptoms. Also described are methods for preparing and using (S)-AV1013, its pharmaceutically acceptable salts as well as pharmaceutically acceptable formulations of the same.
    Type: Grant
    Filed: June 22, 2010
    Date of Patent: February 21, 2012
    Assignee: MediciNova, Inc.
    Inventors: Kirk W. Johnson, Matthew I. Gross, Federico C. A. Gaeta
  • Publication number: 20110275664
    Abstract: The present invention is directed to the use of ibudilast for treating addictions, including drug and behavioral addictions. In particular, ibudilast is used to diminish the dopamine-mediated reward associated with addictions and to treat withdrawal syndromes after discontinuance of addictive drug use or behavior. In addition, methods are provided for preventing or inhibiting relapse in human subjects having a history of methamphetamine addiction or dependence by the administration of an effective amount of ibudilast.
    Type: Application
    Filed: March 28, 2011
    Publication date: November 10, 2011
    Inventors: Kirk W. Johnson, Linda May Rothblum Watkins
  • Publication number: 20110237512
    Abstract: Methods for treating bleeding disorders using non-anticoagulant sulfated polysaccharides (NASPs) as procoagulants are disclosed. NASPs can be administered as single agents, or in combination with one another, or with other medications (such as factors VII, VIII and IX) to promote hemostasis. In particular, the use of NASPs in treatment of bleeding disorders, including congenital coagulation disorders, acquired coagulation disorders, and trauma induced hemorrhagic conditions is described.
    Type: Application
    Filed: September 29, 2010
    Publication date: September 29, 2011
    Inventor: Kirk W. Johnson
  • Publication number: 20110117213
    Abstract: The invention provides a method of improving one or more clinical outcomes of an individual experiencing an acute respiratory attack. The acute respiratory attack may include acute reversible bronchospasm, severe acute bronchospasm, or acute exacerbation of asthma. The method includes administering to an individual suffering from an acute respiratory attack an effective amount of bedoradrine or a pharmaceutically acceptable salt thereof in combination with a standard of care (SOC) treatment regimen.
    Type: Application
    Filed: November 17, 2010
    Publication date: May 19, 2011
    Inventors: Kazuko MATSUDA, Yuichi Iwaki, Kirk W. Johnson
  • Patent number: 7915285
    Abstract: The present invention is directed to the use of ibudilast for treating addictions, including drug and behavioral addictions. In particular, ibudilast is used to diminish the dopamine-mediated reward associated with addictions and to treat withdrawal syndromes after discontinuance of addictive drug use or behavior.
    Type: Grant
    Filed: September 26, 2006
    Date of Patent: March 29, 2011
    Assignees: The Regents of the University of Colorado, Medicinova, Inc.
    Inventors: Kirk W. Johnson, Linda May Rothblum Watkins
  • Publication number: 20110039873
    Abstract: The substituted pyrazolo[1,5-a]pyridine compounds in accordance with Formula 1 are strong inhibitors of phosphodiesterase and c-Jun N-terminal kinase activity. Accordingly, Formula 1 compounds are candidate therapeutics for treating disease states such as cancer, neuropathic pain, inflammation as well as cognitive disorders such as Parkinson's Disease.
    Type: Application
    Filed: June 8, 2010
    Publication date: February 17, 2011
    Inventors: Federico C.A. GAETA, Kirk W. JOHNSON, Matthew I. GROSS, Annemarie LEDEBOER
  • Publication number: 20100324082
    Abstract: Enantiomerically pure (S)-2-amino-1-(2-isopropylpyrazolo[1,5-a]pyridin-3-yl)propan-1-one, (S)-AV1013, is a candidate therapeutic for treating neuroathic pain, addiction behavior and drug withdrawal symptoms. Also described are methods for preparing and using (S)-AV1013, its pharmaceutically acceptable salts as well as pharmaceutically acceptable formulations of the same.
    Type: Application
    Filed: June 22, 2010
    Publication date: December 23, 2010
    Inventors: Kirk W. Johnson, Matthew I. Gross, Federico C.A. Gaeta
  • Patent number: 7829549
    Abstract: Methods for treating bleeding disorders using non-anticoagulant sulfated polysaccharides (NASPs) as procoagulants are disclosed. NASPs can be administered as single agents, or in combination with one another, or with other medications (such as factors VII, VIII and IX) to promote hemostasis. In particular, the use of NASPs in treatment of bleeding disorders, including congenital coagulation disorders, acquired coagulation disorders, and trauma induced hemorrhagic conditions is described.
    Type: Grant
    Filed: April 13, 2009
    Date of Patent: November 9, 2010
    Assignees: Baxter International Inc., Baxter Healthcare S. A.
    Inventor: Kirk W. Johnson
  • Patent number: 7767654
    Abstract: Methods for treating bleeding disorders using non-anticoagulant sulfated polysaccharides (NASPs) as procoagulants are disclosed. NASPs can be administered as single agents, or in combination with one another, or with other medications (such as factors VII, VIII and IX) to promote hemostasis. In particular, the use of NASPs in treatment of bleeding disorders, including congenital coagulation disorders, acquired coagulation disorders, and trauma induced hemorrhagic conditions is described.
    Type: Grant
    Filed: May 27, 2005
    Date of Patent: August 3, 2010
    Assignees: Baxter International, Inc., Baxter Healthcare S.A.
    Inventor: Kirk W. Johnson